SCHEMBL3932115

SCHEMBL3932115

COC(=O)c1c(-c2ccc(Cl)cc2)csc1N

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.76
HSD17B10 Q99714 6/20 0.76
MAPT P10636 5/20 0.76
MAPK1 P28482 2/20 0.76
TSHR P16473 1/20 0.76
PRKCZ Q05513 11/20 0.74
HPGD P15428 4/20 0.74
LMNA P02545 2/20 0.74
MEN1 O00255 2/20 0.74
KMT2A Q03164 2/20 0.74
GAA P10253 1/20 0.67
RECQL P46063 1/20 0.67
TP53 P04637 1/20 0.57
MDM2 Q00987 1/20 0.57
PRKCI P41743 2/20 0.52
SLC6A4 P31645 1/20 0.50
SLC6A3 Q01959 1/20 0.50
USP2 O75604 1/20 0.48
ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1899041 0.86 PRKCZ (0.70) ALDH1A1HSD17B10MAPTMAPK1TSHR
SCHEMBL8288639 0.85 ALDH1A1 (0.76) ALDH1A1HSD17B10MAPTMAPK1TSHR
SCHEMBL2182710 0.85 PRKCZ (1.00) ALDH1A1HSD17B10MAPTMAPK1TSHR
SCHEMBL3995640 0.85 ALDH1A1 (0.76) ALDH1A1HSD17B10MAPTMAPK1TSHR
SCHEMBL688523 0.85 PRKCZ (1.00) ALDH1A1HSD17B10MAPTMAPK1TSHR
SCHEMBL690269 0.85 PRKCZ (1.00) ALDH1A1HSD17B10MAPTMAPK1TSHR
SCHEMBL12271891 0.85 PRKCZ (0.68) ALDH1A1HSD17B10MAPTMAPK1TSHR
SCHEMBL6927654 0.83 PRKCZ (0.66) ALDH1A1HSD17B10MAPTMAPK1TSHR
SCHEMBL2369108 0.81 PRKCZ (0.63) ALDH1A1HSD17B10MAPTMAPK1TSHR
SCHEMBL15940253 0.81 KDM4E (0.56) ALDH1A1HSD17B10MAPTMAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069288-A1 Novel therapeutic compounds ABBVIE INC. 2009-03-12 US disclosed
WO-2009011850-A2 NOVEL THERAPEUTIC COMPOUNDS ABBOTT LABORATORIES (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069288-A1 Novel therapeutic compounds MAP3K20, RPS6KB1, MAP3K1 ALDH1A1 1426/4885HSD17B10 1621/4885MAPT 3755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.